← Back to the boardNews
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
Why it’s here: FDA is requiring GLP-1 drug makers to warn patients and doctors of a new safety risk, a direct US federal regulatory action with policy and market implications.
Trace across the boardItem
6d agoSTATSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionFDA ordered GLP-1 drug makers to add safety labeling warning patients and doctors of a potential risk of the rare eye condition NAION. Biotech9 linked
Coverage
1 outlets · first seen 6d agoConnected
6 links- NewsUS FDA orders new eye risk warnings for Ozempic, ZepboundBoth involve Food and Drug Administration, GLP-1 drugs
- NewsFDA warns against online weight-loss drugs containing uncertain ingredientsBoth involve Food and Drug Administration
- HillComments due: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for FeedbackBoth involve Food and Drug Administration
- HillComments due: Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft GuidanceBoth involve Food and Drug Administration
- NewsSTAT+: GLP-1s are given an FDA warning for rare eye condition riskBoth involve Food and Drug Administration
- HillComments due: Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation CapabilitiesBoth involve Food and Drug Administration
About
- Food and Drug Administration